Real-World Patients’ Diagnosis-to-Treatment Journey with Nontuberculous Mycobacterial Pulmonary Disease: A Cross-Sectional Survey
Authors:
Open Access
- 10 July 2024
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (8) , 1907-1920
Abstract
Introduction: The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. Methods: We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Results: Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient’s symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were “entirely satisfied” with their patients’ treatment outcomes. Conclusions: Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies.Keywords
This publication has 26 references indexed in Scilit:
- Global Epidemiology of Nontuberculous Mycobacterial Pulmonary DiseaseClinics in Chest Medicine, 2023
- Risk Factors for Nontuberculous Mycobacterial Pulmonary DiseaseChest, 2023
- Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary DiseaseChest, 2023
- Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic reviewInternational Journal of Infectious Diseases, 2022
- Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary DiseaseChest, 2022
- A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspectiveExpert Review of Respiratory Medicine, 2021
- Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimationRespiratory Medicine, 2020
- Treatment Duration and Disease Recurrence Following the Successful Treatment of Patients With Mycobacterium avium Complex Lung DiseaseChest, 2020
- Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in JapanRespiratory Medicine, 2019
- Studies on the Epidemiology of Nontuberculous Mycobacteriosis in JapanAmerican Review of Respiratory Disease, 1988